An interventional study of Pelvic floor muscle training in Myotonic Dystrophy Type 1 and Urinary Incontinence, sponsored by Université de Sherbrooke. Recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-24.
Sponsored by Université de Sherbrooke · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Myotonic Dystrophy with a site in Canada — 13 open to participants now, 16 under way, 4 of them phase 3. Myotonic Dystrophy · Canada.
Among the 28 studies in Myotonic Dystrophy with a site in Canada, this one is the 21st largest by planned enrollment of the 25 interventional ones that give a count, is one of 8 that started in 2024, is one of 8 with no phase, reaches primary completion later than 4 of the 15 other live ones, and was the 18th registered.
127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.
Browse Myotonic Dystrophy studies →13 of the 28 studies in Myotonic Dystrophy with a site in Canada are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in Canada, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
PepGen Inc · Sites in Canada
Sanofi · Sites in Canada, United States, Argentina and 3 more countries
Ages 10–55
PepGen Inc · Sites in Canada, New Zealand, Korea, Republic of and 1 more country
Ages 16–65
ARTHEx Biotech S.L. · Sites in Canada, United States, France and 4 more countries
Ages 18–64
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 11 · Phase 3 7
First in 2008; this study’s year is marked. 8 started in 2024.
This study's planned enrollment of 12 is below the median of 40 across 68 interventional studies indexed under Myotonic Dystrophy.
Median enrollment 32 across the 25 interventional studies, 100 across the 3 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 28 have an industry lead sponsor. The 10 most frequent:
Université de Sherbrooke is the lead sponsor of 298 studies on the registry; 67 are open to participants now.
Université de Sherbrooke has 2 studies filed under Myotonic Dystrophy — fewer than ten, so there is no comparison to draw.
7 of the studies in Myotonic Dystrophy with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05004129Phase 3AMO Pharma LimitedSafety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy | 2026-12-31 |
| NCT03981575Virginia Commonwealth UniversityEstab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | 2026-12-01 |
| NCT06316778Université de SherbrookePelvic Floor Muscle Training for Women with Myotonic Dystrophy | 2026-12-30 |
| NCT06138743Sarepta Therapeutics, Inc.Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy | 2026-12-31 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
Add all 7 to your calendar (.ics) → With an account.
Among the 28 studies in Myotonic Dystrophy with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Myotonic dystrophy type 1 (DM1) is a neuromuscular disease characterized by multisystem manifestations. DM1 can affect the urinary system through the impact of the pelvic floor muscles (PFM). Urinary incontinence can occur in this situation and is often offset with compensatory measures without restoring the PFM function (e.g. sanitary pads). PFM training have already been shown to be effective in reducing or even eliminating urinary incontinence in the general population. However, no study has been the subject of this modality in people with DM1. Having recently shown that it is possible to gain strength with DM1, a strengthening protocol targeting PFM could prove effective in treating urinary incontinence. The objectives of this study are i) to assess the feasibility and acceptability of PFM training and ii) to investigate the effects of PFM training in women with DM1 with adult phenotype. A quasi-experimental study will be conducted with 12 women having a confirmed diagnosis of DM1 with urinary incontinence. Participants will follow a 12-week PFM training program, comprising weekly sessions with an experienced physiotherapist as well as a home exercise program. Outcomes measures will be assessed at baseline and at post-treatment and will include: feasibility and acceptability variables, frequency of urinary incontinence, urogynecological symptoms and their impact on quality of life, morphometry and function of PFM, and the perceived improvement following the treatments. This study has the potential to improve the management of urinary incontinence and support the implementation of pelvic floor rehabilitation services in this population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Pelvic floor muscle training
12 weekly sessions of 60 minutes with an experienced physiotherapist, including pelvic floor muscles (PFM) exercises with biofeedback, teaching home exercises and education.
Percentage of attended treatment sessions
To determine feasibility, the patients' adherence to treatment sessions will be recorded (present vs absent) as well as reasons for non-attendance.
Time frame: Through treatment completion (session 1 to 12; 12 weeks of treatment)
Percentage of home exercises performed
1. The adherence rate to home exercises for each treatment group will be assessed using a daily diary. The participants will record the frequency of the exercises completed. 2. To determine feasibility by assessing adherence to treatment sessions.
Time frame: Through treatment completion (session 1 to 12; 12 weeks of treatment)
Retention rate
To determine feasibility by assessing the percentage of participants completing the post-treatment assessment. Reason for dropouts will be compiled.
Time frame: Baseline to Post-treatment assessment (2-week post-treatment)
Recruitment rate
To determine feasibility by assessing the percentage of participants included versus the participants screened. The barriers and reasons for refusing to participate as well as the reasons for exclusion will be documented.
Time frame: Baseline
Intervention Acceptability Questionnaire
The Intervention Acceptability Questionnaire will be used to assess the participants' acceptability of the interventions. This questionnaire consists of 4 items measured on a VAS scale (Minimum value: 0; Maximum Value: 10). Each item is analyzed separately, with a greater score meaning higher acceptability of the intervention. This outcome measure will contribute to identifying factors limiting the acceptability of each program.
Time frame: At baseline and after 12 weeks of treatment
Change in the frequency of urinary incontinence episodes
Evaluated with the 7-day bladder diary (number of leak/week).
Time frame: Baseline to post-treatment (after the 12-week program)
Change in urinary incontinence symptoms
Evaluated with the International Consultation Incontinence Questionnaire (ICIQ-UI-SF) Ranging from 0 to 21, higher scores indicate worse outcome (more urinary incontinence symptoms and a higher impact on their quality of life).
Time frame: Baseline to post-treatment (after the 12-week program)
Change in pelvic floor disorder symptoms
Evaluated with the Pelvic Floor Disorder Inventory (PFDI). Ranging from 0 to 300, higher scores indicate worse outcome (more pelvic floor disorder symptoms).
Time frame: Baseline to post-treatment (after the 12-week program)
Change in pelvic floor disorder symptoms related impact on quality of life
Evaluated with the Pelvic Floor Impact Questionnaire (PFIQ-SF). Ranging from 0 to 300, higher scores indicate a worse outcome (higher impact on their quality of life).
Time frame: Baseline to post-treatment (after the 12-week program)
Change in pelvic floor muscles morphometry
Evaluated with transperineal ultrasound.
Time frame: Baseline to post-treatment (after the 12-week program)
Change in pelvic floor muscles function
Evaluated with dynamometry.
Time frame: Baseline to post-treatment (after the 12-week program)
Patient's satisfaction
Evaluated with Patient satisfaction questionnaire (PSQ) ranging from "completely satisfied" to "not satisfied at all".
Time frame: Post-treatment (after the 12-week program)
Patient's global impression of change
Evaluated with Patients' Global Impression of Improvement (PGI-I). Ranging from 1 "very much better" to 7 "very much worse" on a 7-point likert scale.
Time frame: Post-treatment (after the 12-week program)
Patient's estimated improvement
Evaluated with Estimated percent improvement (EPI). Ranging from 0 "no amelioration" to 100 "complete amelioration".
Time frame: Post-treatment (after the 12-week program)
Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.
Of 26 interventional studies with no phase under Myotonic Dystrophy, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 33 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.